Biomaterials Review Time

Elsevier gives more timing visibility here than many publishers do.

The public official page tells you:

• submission to first decision is about 5 days
• submission to decision after review is about 38 days
• submission to acceptance is about 112 days
• acceptance to online publication is about 2 days
• acceptance rate is about 11%

It does not tell you:

• what share of that 5-day first decision is rejection versus transfer-ready revision
• how timing differs across material classes and biological-model burden
• why some author-reported rejections take much longer than the dashboard suggests

That is why it helps to pair the official dashboard with SciRev community experience.

That is the useful planning model. The journal is fast enough to punish owner mismatch quickly, but not fast enough to be treated like a short-turnaround venue.

Biomaterials often feels fast because the editor can see very early whether the manuscript has the right evidence chain.

Papers can move well when:

• the material intervention is central
• the biological mechanism is visible
• the benchmark is credible
• the application claim is proportionate to the model

Those papers are easier to classify and easier to review coherently.

The slower cases are the manuscripts where the materials story and the biology story are not aligned cleanly enough.

Common sources of delay are:

• strong characterization with thin biological validation
• ambitious translational language built on weak model support
• missing mechanistic bridge from material property to biological outcome
• weak or unrealistic comparators

That is why the review cycle can still feel heavy even at a journal with a fast dashboard.

That profile matches the timing posture. Biomaterials is not just asking whether a paper is publishable. It is asking whether it is a strong owner paper for the field.

This matters because timing pain in biomaterials publishing is often an owner mismatch rather than a pure review-speed problem.

Directionally, the open citation signal is up from 13.06 in 2023 to 13.17 in 2024 after a modest normalization from the 2021 peak. That is a healthy sign for a mature specialty journal. It suggests the journal is not relaxing standards to preserve relevance. It is still publishing papers the field reuses.

Review-time data hides the real lesson at Biomaterials:

• a fast first decision does not mean the paper is safe
• accepted papers still have to survive a serious two-sided review on materials and biology
• the biggest timing variable is whether the paper really behaves like a Biomaterials paper rather than a materials paper with biological garnish

That is why elapsed time matters less than the evidence-chain quality.

In our pre-submission review work with Biomaterials manuscripts, the timing mistake we see most often is authors assuming that good material characterization plus a small amount of biology will still be worth a shot at a flagship biomaterials venue.

It usually is not.

The papers that move best here usually have:

• a clear material-biology mechanism
• validation strong enough for the claim
• a benchmark that makes the result interpretable
• fewer signs that the translational language outruns the model

Those traits improve timing because they reduce the chance of a fast editorial stop or a slow review cycle ending in the same answer.

For Biomaterials, speed matters less than evidence-chain quality and owner fit.

That is why the better next reads are:

• Biomaterials submission guide
• Biomaterials impact factor
• How to avoid desk rejection at Biomaterials
• How to choose the right journal for your paper

A Biomaterials fit check is usually more useful than staring at the five-day first-decision number.

Biomaterials review time is efficient but still fundamentally multi-month. The official dashboard is one of the clearest in the field, and it says the accepted-paper path is about 112 days. Authors should trust that more than the fantasy that a fast desk signal means a fast journal overall.